Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring di
- PDF / 1,729,758 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 79 Downloads / 163 Views
HEPATOBILIARY
Gadoxetic acid‑enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression Aboelyazid Elkilany1 · Dominik Geisel1 · Tobias Müller2 · Andreas Fischer2 · Timm Denecke3 Received: 15 June 2020 / Revised: 20 August 2020 / Accepted: 30 August 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose To investigate the added value of gadoxetic acid-enhanced MRI in monitoring liver function and disease progression in patients with primary sclerosing cholangitis (PSC). Methods We retrospectively identified 104 consecutive patients (75 males; mean age 41.98 ± 12.5 years) with confirmed diagnosis of PSC who underwent 227 gadoxetic acid-enhanced MRI examinations between January 2008 and May 2019. Relative enhancement (RE) of the liver was correlated with the results of liver function tests (LFTs), scoring models (Model for End-Stage Liver Disease (MELD) score, Mayo Risk Score (MRS), Amsterdam-Oxford model (AOM)), and qualitative MRI findings. In addition, results were analyzed separately for excretory MRI examinations (n = 164) and nonexcretory examinations (n = 63) depending on excretion of gadoxetic acid into the common bile duct in the hepatobiliary phase (HBP). Results There was a significant correlation of RE with MRS (r = − 0.652), MELD score (r = − 0.474), AOM (r = − 0.468), and LFTs (P
Data Loading...
